Investing in biotech can be a fun challenge.
There’s a lot of fizzers out there…but if you bag a winner, the gains could be huge.
But don’t be fooled. It’s not easy to make those kinds of returns in this turbulent industry.
There are a lot of variables you need to be aware of before venturing into biotech stocks — potential for big gains comes with lots of risks.
That’s why Money Morning editor Harje Ronngard has put together a brand-new report called: ‘How to Invest in Biotech Stocks’.
Download a copy today and you’ll learn about:
- Why some biotechs could shoot higher: Learn why some biotech’s share prices skyrocket overnight. By the end of this report you’ll understand why some companies achieve this kind of meteoric rise while others fail.
- Why investing in biotech may not be for everyone (even you): While some huge gains are possible in the world of biotech, the sector isn’t without its risks. Ask these questions when evaluating biotech stocks to determine if they’re a potential winner or if they’re fighting a losing battle.
- How to deal with unknown variables in the industry: Research and development, clinical tests, regulatory hurdles, patents, production…a hiccup in any of these areas can cripple a hopeful biotech. But use these strategies for a chance to lock in any potential gains while aiming to minimise losses from volatile biotechs.
You’ll learn all this and more in my brand-new report: ‘How to Invest in Biotech Stocks’.
To get your free copy — right now — enter your email address in the box below and click ‘Send My FREE Report’. You’ll get a downloadable PDF file delivered to your inbox within the next five minutes.
How Money Morning can make you a better, richer investor
Edited by Harje Ronngard, with contributions from Sam Volkering and Greg Canavan, Money Morning isn’t afraid to tell it like it is. From calling politicians out on the big issues, to taking the mighty housing industry on single-handedly, Money Morning exists to cut through the hype and help you make sense of the stories that REALLY make a difference to your wealth.
Harje Ronngard is the lead Editor at Money Morning. With an academic background in finance and investments, Harje knows how simple, yet difficult investing can be. He has worked with a range of assets classes, from futures to equities. But he’s found his niche in equity valuation. There are two questions Harje likes to ask of any investment. What is it worth? And how much does it cost? These two questions alone open up a world of investment opportunities, which Harje shares with Money Morning readers each day.
Harje and the Money Morning team cover share market developments, company announcements and economic events that may affect your wealth. They’ll take anyone to task — banks, governments, big business — if they think someone is trying to pull a fast one with your money.
Whether you agree with Harje, Sam, Greg and the rest of the Money Morning team or not, you’ll find their common-sense, thought-provoking arguments well worth a read — and you’ll soon realise why Money Morning is the biggest circulation daily financial email in Australia.
But don’t take my word for it — start your Money Morning adventure today…
Money Morning is 100% free and delivered to your inbox every morning, six days a week. You’ll never be charged a cent to read it.
No-spam pledge: We will NEVER rent, sell or give away your email address to anyone for any reason. You can unsubscribe from Money Morning anytime, in a few clicks, if you decide you no longer wish to receive it.
All advice is general advice and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.
Calculating Your Future Returns: The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in this report are forecasts and may not be a reliable indicator of future results. Any potential gains in this do not include taxes, brokerage commissions, or associated fees. Please seek independent financial advice regarding your particular situation. Investments in foreign companies involve risk and may not be suitable for all investors. Specifically, changes in the rates of exchange between currencies may cause a divergence between your nominal gain and your currency-converted gain, making it possible to lose money once your total return is adjusted for currency.